Buy Dilantin (Phenytoin) Online — Foundational Hydantoin Anticonvulsant for Tonic-Clonic Seizures, Focal Seizures & Status Epilepticus

🔑 Core identity in one paragraph

Phenytoin (originally called diphenylhydantoin) is a hydantoin-class anticonvulsant that stabilises inactivated voltage-gated sodium channels in neurons, preventing the rapid firing that generates seizure activity. Its distinctive features include non-linear (Michaelis-Menten) pharmacokinetics that require therapeutic drug monitoring, extensive CYP450 metabolism and induction driving many drug interactions, and a spectrum of characteristic long-term adverse effects (gingival hyperplasia, hirsutism, coarsening of features, osteomalacia) that shape its modern role.

🧪 Why phenytoin transformed epilepsy treatment

Before phenytoin, epilepsy was treated primarily with phenobarbital and bromides, both of which caused substantial sedation that impaired quality of life. Phenytoin's discovery in 1938 as an anticonvulsant that suppressed seizures without producing sedation was revolutionary. It allowed people with epilepsy to work, drive, and function normally — a transformation that fundamentally changed the social experience of living with epilepsy. Phenytoin dominated epilepsy prescribing for the next 50 years.

✅ Clinical role today

• Status epilepticus emergency management (second-line after benzodiazepines)
• Focal (partial) seizures with or without secondary generalization (maintenance)
• Generalized tonic-clonic seizures (maintenance)
• Post-traumatic seizure prophylaxis after severe head injury (7-day protocol)
• Neurosurgical seizure prevention perioperatively
• Trigeminal neuralgia (alternative to carbamazepine)
• Diabetic neuropathy pain in specific settings
• Cost-sensitive chronic epilepsy management in resource-limited settings globally

📅 Development timeline

1908 — original synthesis

Heinrich Biltz synthesises diphenylhydantoin at the University of Kiel, Germany. Anticonvulsant properties not recognised. Compound sits in the chemistry literature for 30 years.

1936 — Merritt and Putnam screen anticonvulsants

Merritt HH and Putnam TJ at Harvard begin systematic screening using their newly developed maximal electroshock seizure model in cats. Parke-Davis provides candidate compounds including phenytoin.

1938 — discovery published in JAMA

"Sodium diphenyl hydantoinate in the treatment of convulsive disorders" published in JAMA. Report of anticonvulsant effect without sedation. Parke-Davis launches phenytoin as Dilantin the same year.

1938-1960 — global adoption

Rapid adoption worldwide as first-line epilepsy treatment. Dominates AED prescribing for decades. Transforms social and functional experience of living with epilepsy.

1956 — non-linear pharmacokinetics recognised

Investigators document phenytoin's Michaelis-Menten (saturable) kinetics, explaining why small dose increases can produce large plasma level jumps. Therapeutic drug monitoring becomes standard.

1970s-1980s — carbamazepine and valproate arrive

Newer AEDs offer alternatives with different profiles. Phenytoin remains widely used but faces competition. Long-term adverse effects (gingival hyperplasia, hirsutism, osteomalacia) become better characterised.

1990s — fosphenytoin approved

Fosphenytoin (Cerebyx) approved 1996 as prodrug for IV/IM use, addressing IV phenytoin's cardiovascular and extravasation concerns (purple glove syndrome). Represents modern refinement of hydantoin therapy.

2000s — new generation AEDs emerge

Levetiracetam (Keppra) 1999, lamotrigine (Lamictal), lacosamide, and others offer newer AEDs with better tolerability and fewer interactions. Phenytoin's first-line role for chronic epilepsy narrows.

2004 — HLA-B*1502 discovery (Chung Nature)

Chung and colleagues identify HLA-B*1502 as strong risk factor for Stevens-Johnson syndrome from carbamazepine and phenytoin, particularly in Han Chinese and other Southeast Asian populations. FDA labelling updated with genetic screening recommendation.

Present — enduring niche roles

Phenytoin retains critical role in status epilepticus emergency management, post-traumatic seizure prophylaxis, and cost-sensitive chronic epilepsy globally. WHO Essential Medicine status ensures continued availability.

🇺🇸 The Harvard-Parke-Davis collaboration

Merritt and Putnam's systematic screening at Harvard Medical School exemplified early 20th-century pharmaceutical drug discovery through animal model testing. Parke-Davis provided access to their chemical library, and the collaboration produced one of the most impactful drug discoveries of the century. The maximal electroshock (MES) model developed for phenytoin screening became the standard preclinical anticonvulsant assay and remained in use for AED discovery for the next 80 years.

✅ Why phenytoin persisted despite newer AEDs

Despite the availability of newer AEDs with better tolerability profiles, phenytoin remains one of the most prescribed anticonvulsants globally. Reasons include: (1) status epilepticus emergency protocols still call for phenytoin/fosphenytoin as second-line after benzodiazepines; (2) post-traumatic seizure prophylaxis has robust evidence for phenytoin; (3) extremely low generic cost supports use in resource-limited settings; (4) decades of clinical familiarity in prescribers; (5) WHO Essential Medicine status ensures continued availability. Modern practice balances these advantages against phenytoin's adverse effect and interaction burden.

🧬 Mechanism step by step

1. Voltage-gated sodium channel target: phenytoin binds the alpha-subunit of neuronal voltage-gated sodium channels (Nav1.1, Nav1.2, Nav1.3, Nav1.6)
2. Selective binding to inactivated state: phenytoin preferentially binds channels in the inactivated conformation that follows depolarisation, not the resting state
3. Prolonged inactivation: bound phenytoin slows recovery of channels from inactivation, extending the refractory period between action potentials
4. Use-dependent block: neurons firing rapidly at high frequency (as in seizures) have more channels in the inactivated state and thus more phenytoin binding
5. Normal neurons spared: neurons firing at physiological rates recover before phenytoin can accumulate on their channels
6. Seizure propagation blocked: the specific attack on high-frequency firing stops seizure spread without affecting normal neuronal function
7. Minimal sedation: unlike phenobarbital and benzodiazepines that enhance GABA (which affects many neurons), phenytoin's use-dependent mechanism spares normal function

🔬 Why use-dependent block matters

The concept of "use-dependent" block is central to understanding phenytoin's advantages and limits. Rapidly firing neurons (as in focal or generalized tonic-clonic seizures) accumulate phenytoin on their sodium channels, blocking further firing. Normal neurons firing at physiological rates (5-50 Hz) do not accumulate the block. This selectivity is why phenytoin controls seizures without impairing cognition or causing sedation like older AEDs. Similar use-dependent sodium channel block is shared by carbamazepine, oxcarbazepine, lamotrigine, and lacosamide — a class-defining mechanism.

✅ Beyond sodium channels: additional actions

While voltage-gated sodium channel block is phenytoin's primary mechanism, at therapeutic concentrations it also modulates: (1) calcium channels (contributing to membrane stabilisation); (2) synaptic vesicle release; (3) calmodulin-dependent processes; (4) folate metabolism (basis for teratogenicity and megaloblastic anaemia). The primary sodium channel effect explains anticonvulsant activity; the secondary effects contribute to specific adverse effects like gingival hyperplasia (calcium-related), teratogenicity (folate-related), and cerebellar toxicity (sodium channels in cerebellar Purkinje cells).

🔑 Phenytoin's distinguishing profile among AEDs

• Non-linear (Michaelis-Menten) pharmacokinetics unique among AEDs — requires monitoring
• IV formulation available (unlike many oral-only AEDs)
• Robust evidence for status epilepticus and post-traumatic seizure prophylaxis
• Extensive CYP450 induction creates many drug interactions
• Characteristic long-term adverse effects (gingival hyperplasia, hirsutism, osteomalacia, cerebellar atrophy) not seen with newer AEDs
• Fetal hydantoin syndrome teratogenicity limits pregnancy use
• Very low cost supports use in resource-limited settings
• Not effective for absence seizures — can worsen them
• Not for myoclonic seizures in juvenile myoclonic epilepsy

🧪 The generational shift in AED first-line

Modern epilepsy treatment has shifted away from phenytoin as first-line chronic maintenance therapy toward newer AEDs (particularly levetiracetam and lamotrigine) that offer better tolerability, fewer interactions, and no long-term cosmetic or metabolic effects. This shift is reflected in current ILAE and AAN guidelines. However, phenytoin retains specific niches: (1) status epilepticus emergency management; (2) post-traumatic seizure prophylaxis; (3) resource-limited settings where cost matters; (4) patients well-controlled on phenytoin for years who prefer not to switch. Understanding these distinctions is central to modern epilepsy prescribing.

⚡ Approved indications

Focal (partial) seizures with or without secondary generalisation

Oral phenytoin chronic maintenance therapy. Effective for focal onset seizures including those that secondarily generalize.

Generalized tonic-clonic (grand mal) seizures

Oral maintenance therapy. Effective for primary generalized tonic-clonic seizures.

Status epilepticus

IV phenytoin (or fosphenytoin) is standard second-line therapy after benzodiazepines fail to terminate status. Loading dose 15-20 mg/kg IV at rate not exceeding 50 mg/min.

Post-traumatic seizure prophylaxis

Seven-day IV/oral phenytoin protocol after severe traumatic brain injury reduces early post-traumatic seizures. Long-term prophylaxis not indicated.

Neurosurgical seizure prevention

Perioperative seizure prophylaxis for supratentorial surgery. Typically 7-day protocol.

Trigeminal neuralgia (off-label)

Alternative when carbamazepine is not tolerated or contraindicated. Not first-line but historically used.

🔴 What phenytoin should NOT be used for

• Absence seizures — can worsen absence spike-and-wave patterns
• Myoclonic seizures — can worsen myoclonic jerks
• Juvenile myoclonic epilepsy as first-line — can worsen the myoclonic component
• Long-term prophylaxis after uncomplicated head injury — only 7-day post-severe TBI protocol
• Chronic maintenance in young women of childbearing age when alternatives work — teratogenicity concern
• Chronic maintenance in patients concerned about cosmetic effects when alternatives work

🧪 Modern first-line versus phenytoin

Current ILAE and AAN guidelines list levetiracetam and lamotrigine as first-line options for focal epilepsy in adults, with phenytoin as an acceptable alternative. For generalized tonic-clonic seizures, valproate and lamotrigine are commonly first-line (except in women of childbearing age where valproate is avoided). Phenytoin's modern niche is greatest in acute settings (status epilepticus, post-traumatic prophylaxis) where IV administration and rapid onset matter, and in patients already well-controlled on phenytoin who prefer not to switch.

🔴 The non-linear kinetics problem

Below approximately 10 mcg/mL plasma level, phenytoin metabolism follows first-order kinetics (elimination proportional to concentration). At therapeutic range (10-20 mcg/mL), the metabolic enzymes (CYP2C9) become saturated, and metabolism shifts toward zero-order (fixed amount eliminated per unit time regardless of concentration). Consequence: a small dose increase can produce a large plasma level jump. Example: increasing from 300 mg to 400 mg daily might raise the level from 12 to 30 mcg/mL, exceeding the therapeutic range and producing toxicity. Small dose adjustments (30-50 mg increments) are essential.

🔬 Why protein binding matters

Phenytoin is 90 percent protein-bound to albumin. The free (unbound) fraction is the pharmacologically active portion. In conditions that reduce albumin (uraemia, hypoalbuminaemia, hepatic disease) or that displace phenytoin from albumin (concurrent valproate, high-dose salicylates), the free fraction rises while the total measured level may appear unchanged. This means total phenytoin levels can be misleading; free levels are more reliable in these clinical situations. Corrected level formulas (Sheiner-Tozer equation) adjust total levels for low albumin.

🕑 Practical dosing implications

• Small dose adjustments only: increments of 30 to 50 mg typically
• Wait 2-4 weeks after any dose change before checking steady-state level (due to prolonged half-life at saturating concentrations)
• Therapeutic drug monitoring essential: target total 10-20 mcg/mL, free 1-2 mcg/mL
• Check free level when albumin is low or valproate is co-prescribed
• Do not double doses when a dose is missed — can cause toxicity
• Extended-release capsules preferred for maintenance (smoother PK profile)
• Suspension bioavailability varies — shake well; consistent formulation

🧪 Therapeutic drug monitoring targets

Total phenytoin serum level

Target: 10 to 20 mcg/mL (40 to 80 micromol/L). Above 20 mcg/mL: toxicity risk. Below 10 mcg/mL: subtherapeutic for many patients.

Free (unbound) phenytoin level

Target: 1 to 2 mcg/mL. More reliable than total level when albumin is low or protein binding is altered.

Timing of level check

Trough level immediately before next dose. After dose change: wait 2 to 4 weeks for steady state given non-linear PK.

When to check

Initiation of therapy; after any dose change; symptoms suggestive of toxicity; new interacting medication started; suspected non-adherence; pregnancy; changes in clinical status affecting protein binding.

🔬 The Sheiner-Tozer correction

In patients with low albumin (below 4.0 g/dL), total phenytoin levels underestimate the pharmacologically active free portion. The Sheiner-Tozer equation adjusts total level for albumin: Corrected level = Measured / (0.2 x Albumin + 0.1). Example: measured 8 mcg/mL total in a patient with albumin 2.5 g/dL corrects to 8 / (0.2 x 2.5 + 0.1) = 8 / 0.6 = 13.3 mcg/mL. This corrected value is used to interpret "true" therapeutic range. Free level measurement (when available) bypasses this correction — target 1-2 mcg/mL.

💚 Adjusting the dose

Due to non-linear kinetics, dose adjustments must be small (typically 30 to 50 mg increments). A simplified rule for adults: if current level is 5-10 mcg/mL: increase by 100 mg/day. If 10-15 mcg/mL: increase by 50 mg/day. Above 15 mcg/mL: increase by 30 mg/day only. Waiting 2 to 4 weeks after each change is essential given the prolonged half-life at higher concentrations. Larger dose jumps can produce dangerous toxicity.

✅ Practical monitoring schedule

Baseline level after loading dose; 1 to 2 weeks after any maintenance dose change; every 6 to 12 months once stable; when new interacting medications are added; when clinical status changes (pregnancy, illness, hospitalisation); when adherence is uncertain; when seizure control changes; before any planned surgery. Free levels are particularly important in critically ill patients, patients with renal or hepatic disease, and patients receiving concurrent valproate.

🔴 Status epilepticus emergency protocol

Time 0-5 min: initial assessment

Airway, breathing, circulation. Check blood glucose. Establish IV access. If prolonged NPO consider thiamine and dextrose IV.

Time 5-20 min: first-line benzodiazepine

Lorazepam 4 mg IV (0.1 mg/kg) OR midazolam 10 mg IM (buccal or nasal alternatives if no IV access) OR diazepam 10 mg IV. May repeat once if seizures continue.

Time 20-40 min: second-line AED (phenytoin role)

Fosphenytoin 20 mg PE/kg IV (equivalent to phenytoin) OR phenytoin 20 mg/kg IV at maximum 50 mg/min rate OR valproate 40 mg/kg IV OR levetiracetam 60 mg/kg IV. All are acceptable; local practice varies.

Time 40-60 min: refractory status

Continuous infusion anaesthetic (midazolam, propofol, pentobarbital) with EEG monitoring. ICU admission. Consider additional second-line agent if not already given.

Super-refractory status

Persistent for over 24 hours despite anaesthetic therapy. Ketamine, hypothermia, ketogenic diet in refractory cases. Neurology and ICU coordinated management.

💉 Phenytoin loading dose for status

Adult: 15-20 mg/kg IV at maximum 50 mg/min rate (approximately 1000-1500 mg for average adult). Given through a large-bore peripheral or central line to reduce risk of extravasation. Cardiac monitoring during infusion — hypotension and bradyarrhythmias possible. If loading dose fails to terminate seizures, additional 5-10 mg/kg may be given. Maximum single loading dose 30 mg/kg total.

🧪 The ESETT trial

The ESETT (Established Status Epilepticus Treatment Trial, NEJM 2019) compared fosphenytoin, levetiracetam, and valproate as second-line agents in benzodiazepine-refractory status epilepticus. All three showed similar efficacy (approximately 50 percent seizure termination) and similar safety. This confirmed that phenytoin/fosphenytoin remains a valid choice alongside newer alternatives. Local practice and drug availability guide choice among the three.

✅ Why phenytoin remains a status epilepticus mainstay

Despite the availability of alternatives (levetiracetam IV, valproate IV), phenytoin (or fosphenytoin) retains a first-choice second-line role in status epilepticus protocols worldwide. Reasons: (1) proven efficacy over decades; (2) IV formulation; (3) protocol simplicity for emergency departments; (4) rapid onset with adequate loading dose; (5) transition to oral maintenance is straightforward. In modern practice, hospitals may use any of fosphenytoin, levetiracetam, or valproate as second-line; ESETT-informed choice is often institution-dependent.

💉 Fosphenytoin advantages over IV phenytoin

Faster infusion rate

Fosphenytoin can be infused at 150 mg PE/min (adults) versus phenytoin's 50 mg/min limit. This means loading doses can be delivered in one-third the time.

Lower extravasation risk

Fosphenytoin is water-soluble and near-physiological pH (~9). Extravasation is much less damaging than with phenytoin (which is very alkaline, pH ~12, and crystallises in tissue causing purple glove syndrome).

IM administration possible

Fosphenytoin can be given intramuscularly when IV access is difficult (e.g., pre-hospital status epilepticus). Phenytoin cannot — it crystallises at IM injection sites.

Lower cardiovascular risk

Reduced hypotension and arrhythmia risk during rapid infusion because propylene glycol vehicle of IV phenytoin is not needed for fosphenytoin.

Dosing in phenytoin-equivalents (PE)

Fosphenytoin is dosed in phenytoin-equivalent units (PE) where 1 mg PE = 1 mg phenytoin. This simplifies conversion.

💜 Purple glove syndrome (with IV phenytoin)

The dreaded complication of IV phenytoin. Extravasation or even proper IV administration through peripheral lines can cause severe skin, subcutaneous tissue, and blood vessel damage due to the alkaline pH and propylene glycol vehicle. Purple, painful discolouration of the hand/limb progresses to necrosis. May require surgical intervention including fasciotomy or amputation in severe cases. Fosphenytoin dramatically reduces this risk and is preferred whenever IV phenytoin would otherwise be given — particularly in peripheral IV settings.

🧪 The cost trade-off

Fosphenytoin costs several times more than IV phenytoin per equivalent dose. In cost-sensitive settings and resource-limited emergency departments, IV phenytoin remains widely used with careful attention to line management (large-bore access, slow infusion at 50 mg/min max, monitoring for extravasation, immediate line change if any discolouration or pain). In well-resourced settings, fosphenytoin is now preferred as standard of care given the substantially better safety profile.

🧠 Focal epilepsy treatment framework

Modern first-line AEDs (ILAE, AAN)

Levetiracetam (Keppra) or lamotrigine (Lamictal) are preferred first-line in adults. Both have better tolerability profiles and fewer drug interactions than phenytoin.

Phenytoin as alternative

Phenytoin remains an acceptable choice, particularly when cost is a concern, when patients are stable on the drug, or in settings where newer AEDs are not readily available. Similar efficacy to newer AEDs in randomised trials.

Loading dose (oral)

Not routine for outpatient chronic maintenance. When rapid therapeutic levels needed: oral loading 15-20 mg/kg divided into 3 doses over 24 hours.

Maintenance dose

Adults: 4-6 mg/kg/day, typically 300-400 mg/day divided BID or TID for extended-release capsules. Once-daily dosing sometimes possible with extended-release.

Extended-release capsules

Preferred for maintenance. Smoother pharmacokinetic profile allows once-daily dosing in some patients. Immediate-release forms typically require BID or TID.

🧪 Efficacy comparison

Direct comparison trials (SANAD trial UK, others) have shown that phenytoin achieves similar seizure control rates to newer AEDs (approximately 60-70 percent 12-month seizure freedom for newly diagnosed focal epilepsy). The differences among first-line options are more about tolerability, adverse effect profile, and drug interactions than about raw efficacy. This is why the choice today weights these considerations heavily rather than efficacy alone.

✅ The stability principle

For patients who have achieved seizure control on phenytoin over years and are tolerating it well, switching to a newer AED risks losing control during the transition and may not provide benefit. The general principle is: continue what works; switch only when there is a specific reason (adverse effects intolerable, planning pregnancy, new interaction concern, patient preference after informed discussion). This principle keeps phenytoin as a common maintenance AED even in the era of newer alternatives.

⚡ Generalized tonic-clonic seizure treatment framework

Primary generalized tonic-clonic (adult)

First-line: valproate (for men and postmenopausal women), lamotrigine, or levetiracetam. Phenytoin acceptable alternative.

Focal to bilateral tonic-clonic

Same AEDs effective as for focal epilepsy. Phenytoin, levetiracetam, lamotrigine all appropriate.

Women of childbearing age

Avoid valproate (highest teratogenicity). Avoid phenytoin if alternatives work. Lamotrigine or levetiracetam preferred.

Juvenile myoclonic epilepsy (has GTC component)

Phenytoin NOT appropriate — can worsen myoclonic component. Valproate first-line (men); levetiracetam or lamotrigine (women).

Combined focal and GTC in same patient

Phenytoin covers both. This is one context where phenytoin's broad activity is useful.

🔴 The juvenile myoclonic epilepsy trap

A common clinical error: patient presents with generalized tonic-clonic seizures. Phenytoin is initiated. Seizures partially controlled but myoclonic jerks (which the patient may not have initially reported) worsen. This is because juvenile myoclonic epilepsy (JME) has three seizure types — GTC, myoclonic, and absence — and phenytoin worsens the myoclonic component. Careful history for morning myoclonic jerks and absence seizures before starting phenytoin can prevent this. If any of these features are present, valproate (men) or lamotrigine/levetiracetam (women) is preferred.

✅ Efficacy is comparable

Phenytoin's efficacy for primary GTC seizures is comparable to other AEDs. The reason it is not first-line in modern guidelines relates to tolerability, drug interactions, and long-term adverse effects rather than efficacy. In patients where phenytoin is chosen (cost considerations, established stability, patient preference), effective seizure control is achievable with appropriate monitoring.

🩹 Post-traumatic seizure prophylaxis framework

Indication

Severe TBI with high risk of early post-traumatic seizures (within 7 days of injury). Risk factors: intracranial hemorrhage, penetrating injury, depressed skull fracture, prolonged coma, seizure at time of injury, cortical contusion.

Standard 7-day protocol

Loading dose 15-20 mg/kg IV (phenytoin or fosphenytoin) followed by maintenance 4-6 mg/kg/day for 7 days. Discontinue after 7 days.

Why 7 days only

Phenytoin reduces early post-traumatic seizures (first 7 days) but does not prevent late post-traumatic epilepsy (weeks to months later). Continuing beyond 7 days does not add benefit and adds adverse effect risk.

Levetiracetam alternative

Increasingly used as alternative given better tolerability and no need for drug monitoring. Similar efficacy to phenytoin for early post-traumatic seizure prophylaxis.

Neurosurgical seizure prevention

Similar 7-day protocol for supratentorial craniotomy, tumor resection, aneurysm clipping. Not indicated for infratentorial surgery.

🧪 Evidence base

Temkin NEJM 1990 established the phenytoin post-traumatic seizure prophylaxis benefit: 7-day phenytoin reduced early post-traumatic seizures by approximately 70 percent versus placebo, without preventing late post-traumatic epilepsy. This remains the definitive study underlying current practice. Subsequent trials comparing levetiracetam to phenytoin have shown similar efficacy with better tolerability of levetiracetam. Many centres now use levetiracetam instead of phenytoin for this indication.

✅ Practical implementation

In a typical severe TBI patient: fosphenytoin loading 20 mg PE/kg IV in the emergency department or ICU, followed by fosphenytoin or phenytoin 100 mg IV/oral TID for 7 days. Check level after loading and daily during ICU course. Discontinue on day 7. If seizures occur despite prophylaxis, treat as established seizures with appropriate AED. Do not continue phenytoin beyond day 7 for pure prophylactic indication — this does not add benefit and adds adverse effect burden.

⚠️ The controversial spontaneous ICH question

For spontaneous intracerebral haemorrhage (non-traumatic), the utility of prophylactic AED is more debated. Current guidelines (AHA/ASA) do NOT recommend routine prophylaxis for spontaneous ICH. Prophylactic phenytoin has been associated with worse outcomes in some observational studies. Prophylaxis is reserved for patients with actual clinical seizures. This distinction between traumatic and spontaneous ICH matters clinically.

💊 The 30-50 mg dose adjustment rule

Due to non-linear kinetics, phenytoin dose adjustments must be small. General rule for adults with current level and target 10-20 mcg/mL: current level 5-10 mcg/mL: increase by 100 mg/day. Current level 10-15 mcg/mL: increase by 50 mg/day. Current level 15-20 mcg/mL: increase by 30 mg/day. Large jumps (e.g., 300 mg to 500 mg) can produce toxicity because the metabolic enzymes saturate.

🕑 Practical administration tips

• Extended-release capsules preferred for maintenance (smoother PK profile)
• Take with food to reduce GI upset (does not significantly affect absorption)
• Same brand/formulation for chronic use (bioavailability differences between generics may affect levels)
• Chewable tablets: chew thoroughly before swallowing
• Suspension: shake vigorously before each dose (settling causes variable dosing)
• Do not double doses if one missed — see missed dose section
• Regular therapeutic drug monitoring is essential
• Adherence critical — missed doses can lead to breakthrough seizures

🔴 Never adjust dose based on symptoms alone

Because phenytoin has both dose-dependent and dose-independent adverse effects, and because tolerance to some side effects develops over time, do not adjust dose based on symptom fluctuations alone. Always base dose adjustments on measured plasma levels. This principle protects against inappropriate under-dosing (breakthrough seizures) or overdosing (toxicity).

👶 Paediatric formulations

Oral suspension (125 mg/5 mL)

Standard paediatric form. Must be shaken vigorously before each dose — settling causes highly variable doses. This is a well-documented problem with phenytoin suspension.

Chewable tablets (50 mg)

For children who can chew reliably. Note these are labelled "phenytoin" but they contain the acid form (not sodium salt) — so 100 mg chewable ? 92 mg extended-release capsule due to salt-content differences.

Extended-release capsules (30, 100 mg)

For children able to swallow capsules. Contain phenytoin sodium.

🔴 Cosmetic effects concern in paediatric practice

Gingival hyperplasia (up to 50 percent of children on chronic phenytoin), hirsutism, and coarsening of facial features are particularly distressing in adolescents. These have contributed to the shift toward newer AEDs (levetiracetam, oxcarbazepine, lamotrigine) for paediatric epilepsy maintenance. When phenytoin is used in children, meticulous dental hygiene and awareness of cosmetic issues are important. For long-term paediatric epilepsy, discuss AED alternatives that lack these effects.

🔬 Paediatric pharmacokinetics

Young children (1-5 years) tend to metabolise phenytoin more rapidly than adults on a mg/kg basis, requiring higher weight-based doses to achieve the same therapeutic levels. Adolescents transition toward adult dosing. Neonates have variable and often prolonged elimination due to immature hepatic function. Therapeutic drug monitoring is particularly important in children given these variable kinetics and the growth-related dose changes needed over time.

✅ Paediatric practical tips

• Shake suspension vigorously before every dose — settling causes serious dose variability
• Measure with appropriate device (syringe or cup) — NOT household teaspoons
• Monitor plasma levels frequently during growth phases
• Emphasise dental hygiene to reduce gingival hyperplasia
• Regular dental cleanings every 3-4 months during phenytoin therapy
• Educate about cosmetic effects and consider alternatives for long-term use
• Discuss with adolescents about interactions with oral contraceptives (see interactions section)

🧪 Why protein binding matters so much

Phenytoin is 90 percent bound to albumin. In hypoalbuminaemia (albumin under 4.0 g/dL), the free fraction increases while the total level appears unchanged or reduced. A patient with albumin 2.0 g/dL and total phenytoin 8 mcg/mL may actually have the pharmacologically active equivalent of 15 mcg/mL total (using Sheiner-Tozer: 8 / (0.2 x 2.0 + 0.1) = 16 mcg/mL). Failing to correct for low albumin can lead to inappropriate dose increases and toxicity. In critical care, ICU, cirrhosis, nephrotic syndrome, or malnutrition settings, this correction is essential.

🔬 The Sheiner-Tozer correction formula

Corrected phenytoin = Measured / (0.2 x Albumin + 0.1) for normal renal function. For patients with CrCl below 20 mL/min: Corrected phenytoin = Measured / (0.1 x Albumin + 0.1). Or better yet: measure free phenytoin level directly (target 1-2 mcg/mL) when available, particularly for critically ill patients, uraemic patients, or patients on concurrent protein-binding-displacing drugs (valproate, high-dose aspirin).

⚠️ When to consider alternative AED

• Severe hepatic impairment: dose prediction unreliable; consider levetiracetam (renally cleared, minimal hepatic metabolism)
• Severe uraemia: protein binding highly abnormal; free level monitoring essential; alternative may be simpler
• Combined renal + hepatic disease: very complex pharmacokinetics; alternative AED preferred if possible
• Multiple concurrent protein-binding-displacing drugs: consider alternative
• Ability to monitor free levels is limited: alternative AED may be safer

✅ Practical approach in complex patients

In ICU, cirrhotic, or uraemic patients: (1) check baseline albumin and creatinine clearance; (2) measure free phenytoin level directly rather than relying on total; (3) if only total available, apply Sheiner-Tozer correction; (4) consider fosphenytoin over phenytoin for IV administration; (5) consider levetiracetam as alternative AED where pharmacokinetics are more predictable. In these settings, levetiracetam has substantially replaced phenytoin in many centres because it avoids the protein binding complications entirely.

🔗 Three interaction mechanisms

Phenytoin as CYP450 inducer

Reduces plasma levels and efficacy of many drugs metabolised by CYP3A4, 2C9, 2C19: oral contraceptives, warfarin (complex), some antihypertensives, some antipsychotics, other AEDs, ART, corticosteroids, statins.

CYP2C9 inhibitors raise phenytoin levels

Amiodarone, fluconazole, isoniazid, cimetidine, disulfiram, sulfonamides, chloramphenicol, some SSRIs. Can rapidly cause phenytoin toxicity.

Protein-binding displacement

Valproate, high-dose salicylates, some NSAIDs, phenylbutazone displace phenytoin from albumin, raising free level even when total appears unchanged. Toxicity can occur with normal-appearing total level.

🔴 The oral contraceptive interaction

Phenytoin's CYP3A4 induction substantially reduces estrogen and progestin levels from oral contraceptives, leading to contraceptive failure and unintended pregnancy. This is a major clinical issue since unintended pregnancy exposes the fetus to teratogenic phenytoin. Women of childbearing age on phenytoin should use alternative contraception: intrauterine devices (IUD, most reliable), Depot medroxyprogesterone injections, higher-dose oral contraceptives (35 mcg ethinyl estradiol minimum), or barrier methods as back-up. This is an important preconception counselling discussion.

🧪 Enteral tube feed interaction

Continuous enteral tube feeds substantially reduce phenytoin oral bioavailability — phenytoin binds to feed components. Standard practice in ICU is to hold tube feeds for 1 to 2 hours before and after each phenytoin dose. Alternatively, use IV or fosphenytoin during periods of enteral feeding. This is a common ICU practice issue that requires nursing awareness.

🔴 Fetal hydantoin syndrome

Craniofacial anomalies

Broad nasal bridge, hypertelorism (widely-spaced eyes), epicanthal folds, ptosis, cleft lip / cleft palate.

Distal digital anomalies

Short fingertips, hypoplastic nails, distal phalangeal hypoplasia (the "fingertip" hallmark).

Growth deficiency

Prenatal and postnatal growth restriction.

Developmental delay

Mild to moderate cognitive impairment in a proportion of exposed children. NEAD study (Meador Lancet Neurol 2013) documented cognitive effects at age 6.

Increased birth defect risk overall

Approximately 6-10 percent major congenital malformation rate versus baseline 2-3 percent (EURAP registry data).

Neonatal haemorrhage

Vitamin K-dependent factor deficiency in newborn; treat with vitamin K1 mm at birth.

🤰 Pregnancy management framework

Preconception counselling

Before pregnancy: discuss teratogenicity; consider switching to lamotrigine or levetiracetam if possible; folate 4-5 mg daily starting at least 3 months before conception; document seizure control; discuss AED level monitoring during pregnancy.

During pregnancy

Continue folate 4-5 mg daily. Level monitoring approximately monthly — phenytoin clearance increases during pregnancy, requiring dose adjustments. Detailed fetal anatomy scan at 18-20 weeks. Aneuploidy screening as usual.

Third trimester

Vitamin K1 supplement (10 mg oral daily) in last month to prevent neonatal haemorrhage. Some centres give this only at delivery instead.

At delivery

Vitamin K1 1 mg IM to newborn (standard). Cord blood phenytoin level if concerns about neonatal toxicity.

Postpartum

Phenytoin clearance returns to non-pregnant levels over 2-6 weeks. Downward dose adjustment often needed to avoid postpartum toxicity. Monitor level.

🔬 Comparative AED teratogenicity (EURAP registry)

EURAP data ranked AED teratogenicity: valproate (highest, approximately 10-14 percent MCM), phenobarbital, phenytoin (approximately 6-9 percent), carbamazepine (approximately 5-6 percent), lamotrigine (approximately 3 percent), levetiracetam (approximately 3 percent, similar to background). This ranking has driven modern preconception AED selection toward lamotrigine and levetiracetam for women planning pregnancy. When these are effective and tolerated, they are preferred over phenytoin.

🍼 Lactation

Phenytoin transfers into breast milk at low concentrations (milk-to-plasma ratio approximately 0.2). Infant exposure is generally below therapeutic threshold. Phenytoin is considered generally compatible with breastfeeding per American Academy of Pediatrics. Watch the infant for sedation, poor feeding, rash. Preconception AED choice for future pregnancies should consider lactation compatibility as one factor.

⚠️ The switching dilemma

Switching AEDs during pregnancy risks breakthrough seizures which are also harmful to fetus and mother. Ideally, AED optimisation occurs BEFORE conception, not during pregnancy. If a woman on phenytoin becomes pregnant unexpectedly, the general recommendation is to continue phenytoin at effective dose (do not switch during pregnancy) with folate supplementation and detailed monitoring — not to switch and risk loss of seizure control. Preconception counselling is essential to avoid this scenario.

✅ Practical management

• Any acute symptom of dose-related toxicity: check phenytoin level; if elevated, reduce dose
• Nystagmus is the earliest sign of drug toxicity — look for horizontal nystagmus on lateral gaze
• Ataxia and incoordination follow at higher levels
• Sedation and encephalopathy occur at even higher levels
• Rash needs urgent evaluation — distinguish benign from SJS/TEN (see section 24)
• Cognitive slowing at therapeutic levels: some patients affected; consider alternative
• Chronic effects (gingival, hirsutism, osteomalacia, cerebellar) develop over years
• Folate supplementation (1-5 mg daily) mitigates megaloblastic anaemia and reduces cognitive effects

🧪 Correlation of level with symptoms

The classic teaching: nystagmus at 20 mcg/mL, ataxia at 30 mcg/mL, drowsiness at 40 mcg/mL, coma at 100 mcg/mL. In practice, individual sensitivity varies substantially. Some patients tolerate 25 mcg/mL without symptoms; others develop nystagmus at 15 mcg/mL. Clinical assessment plus level guides individualisation. Any symptomatic patient with elevated level warrants dose reduction.

✅ When levetiracetam is preferred

• Newly diagnosed focal or generalized epilepsy in most patients
• Women of childbearing age (much safer teratogenicity profile)
• Patients on complex polypharmacy (avoids interactions)
• Patients concerned about cosmetic effects
• Patients with juvenile myoclonic epilepsy (covers all three seizure types)
• Elderly with multiple comorbidities and interactions
• Post-traumatic seizure prophylaxis (equivalent efficacy, better tolerability)
• Status epilepticus (ESETT-supported second-line alternative)

🔑 When phenytoin retains a role

• Patient stable on phenytoin for years, tolerating well, achieving control
• Cost-limited settings where phenytoin generics are dramatically cheaper
• Levetiracetam behavioural adverse effects intolerable (aggression, depression)
• Emergency status epilepticus in institution where phenytoin/fosphenytoin protocol is standard
• Post-traumatic prophylaxis where phenytoin protocol established
• Renal impairment where levetiracetam dosing is complex (though phenytoin free level monitoring also complex)

🧪 The behavioural trade-off

Levetiracetam's major drawback is behavioural adverse effects: irritability, depression, mood changes, and aggression affect approximately 5-15 percent of users, often within days of starting. This can be severe enough to require discontinuation. Some patients (particularly those with pre-existing mood disorders, developmental delays, or on other CNS-active medications) are more susceptible. In patients who develop these effects, phenytoin remains a reasonable alternative despite its own adverse effects.

✅ When carbamazepine is preferred

• Trigeminal neuralgia (first-line)
• Bipolar disorder (mood stabiliser role)
• Focal epilepsy where cosmetic effects a concern (no gingival/hirsutism)
• Patients intolerant of phenytoin cosmetic effects

🔑 When phenytoin is preferred over carbamazepine

• Status epilepticus (IV formulation)
• Post-traumatic seizure prophylaxis (IV loading)
• Emergency parenteral use
• Concern about carbamazepine bone marrow effects
• Concern about carbamazepine hyponatraemia (elderly, heart failure)
• Prior carbamazepine adverse reaction

🧪 Shared SJS risk in Asian populations

Both phenytoin and carbamazepine share the HLA-B*1502 risk for Stevens-Johnson syndrome / toxic epidermal necrolysis in Han Chinese and other Southeast Asian populations. FDA recommends genetic screening before initiation in these populations. Choice between phenytoin and carbamazepine does not avoid this risk — both should be avoided in HLA-B*1502-positive patients.

✅ When valproate is preferred

• Juvenile myoclonic epilepsy (JME) — particularly in men and postmenopausal women
• Absence seizures
• Myoclonic seizures
• Broad-spectrum coverage needed for mixed seizure types
• Bipolar disorder or migraine prophylaxis (dual indication)
• Trigeminal neuralgia unresponsive to first-line

🔑 When phenytoin is preferred over valproate

• Women of childbearing age (valproate is highest teratogenicity)
• Status epilepticus (IV loading protocol)
• Post-traumatic prophylaxis
• Pure focal or focal-to-bilateral tonic-clonic (no absence/myoclonic component)
• Weight-conscious patients (valproate causes weight gain)
• Patients with pre-existing thrombocytopenia or hepatic disease

🔴 Valproate + phenytoin combination alert

If both drugs are used together, valproate displaces phenytoin from protein binding — raising free phenytoin level even when total appears unchanged. Toxicity can occur at seemingly therapeutic total phenytoin levels. Free level monitoring is essential in this combination. Additionally, valproate can raise phenytoin levels via CYP inhibition. Combination should be used carefully with regular monitoring.

🔴 Severe adverse effects to recognise

Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN)

Life-threatening. Widespread rash with mucosal involvement and skin peeling. HLA-B*1502-associated in Asian populations. Screen before starting in Asian populations. See section 24.

DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

Widespread rash with fever, lymphadenopathy, eosinophilia, and organ involvement (liver, kidney, heart, lung). Onset 2-8 weeks after starting. Requires immediate discontinuation. See section 25.

Hepatotoxicity

Ranges from asymptomatic LFT elevation to fulminant hepatic failure. Part of DRESS syndrome. May be idiosyncratic. Discontinue if suspected.

Purple glove syndrome

IV phenytoin causing severe soft tissue damage from extravasation or even proper administration. Can require surgery including amputation. Prevention: fosphenytoin or central line + slow rate. See section 26.

Cardiovascular collapse (IV administration)

Hypotension, bradycardia, arrhythmias, cardiac arrest during rapid IV infusion. Prevention: max 50 mg/min rate, cardiac monitoring, use fosphenytoin.

Cerebellar toxicity

Acute: nystagmus, ataxia at high levels. Long-term: cerebellar atrophy with permanent ataxia in some chronic users. See section 28.

Osteomalacia and osteoporosis

Long-term chronic use disrupts vitamin D and calcium metabolism. Increases fracture risk. See section 27.

Fetal hydantoin syndrome

In utero exposure causes characteristic craniofacial, digital, growth, and cognitive anomalies. See section 17.

Aplastic anaemia and blood dyscrasias

Rare idiosyncratic reactions including aplastic anaemia, agranulocytosis, thrombocytopenia.

Neonatal haemorrhagic disease

Vitamin K-dependent factor deficiency in newborns of women on phenytoin. Preventable with vitamin K1 to mother and infant.

⚠️ Warning signs requiring immediate medical attention

• Widespread rash, especially with fever, mucosal involvement, or peeling
• Facial swelling, lymphadenopathy, eosinophilia (DRESS)
• Yellow skin or eyes, dark urine, right upper quadrant pain (hepatitis)
• Fever, malaise, chills during first weeks of therapy
• Purple discolouration or pain at IV site
• Palpitations, syncope, chest pain during IV administration
• Severe ataxia, slurred speech, confusion (elevated level)
• Nystagmus that worsens (elevated level)
• Unusual bruising or bleeding
• New or worsening weakness
• Sudden vision changes

🔑 Higher-risk patient groups for severe adverse effects

• Asian populations (HLA-B*1502) — SJS/TEN risk 100-fold higher; screen before starting
• Prior severe reaction to any anticonvulsant
• Concurrent CYP inhibitor drugs (raising phenytoin level)
• Hypoalbuminaemia (raising free phenytoin)
• Severe hepatic disease
• Pregnancy (teratogenic risk)
• Elderly with polypharmacy and reduced protein binding
• Children (cosmetic and cognitive effects most relevant)
• Chronic users over years (cumulative bone, cerebellar, cognitive effects)
• Peripheral IV administration in emergency settings (purple glove syndrome)

✅ Overall risk perspective

Phenytoin has one of the most extensive adverse effect profiles of any AED. This is one reason the shift toward newer AEDs has been so pronounced in modern epilepsy practice. However, in appropriate patients with attention to monitoring, dose control, and early recognition of adverse effects, phenytoin can be used safely for decades — there are patients who have taken phenytoin for 40+ years without major issues. The key is patient selection, education, monitoring, and prompt response to any warning signs. In modern practice, phenytoin's specific niches (status epilepticus, post-traumatic prophylaxis, cost-limited chronic use) balance these risks against its established efficacy.

🦷 Gingival hyperplasia characteristics

Prevalence

30-50 percent of chronic phenytoin users. Higher in children and adolescents than adults. Correlates modestly with dose and level.

Onset

Usually appears within 3 to 6 months of starting therapy. Progresses gradually over months to years if untreated.

Appearance

Gums become firm, thickened, and enlarged, particularly at the front teeth. In severe cases, gum tissue covers a significant portion of tooth surfaces.

Mechanism

Not fully understood. Involves fibroblast proliferation, extracellular matrix accumulation, and altered calcium and folate metabolism. Poor dental hygiene worsens the reaction dramatically.

Complications

Difficulty chewing, altered speech, dental hygiene difficulties, cosmetic distress, secondary periodontal disease, tooth malposition, difficulty maintaining dentures.

✅ Prevention: dental hygiene protocol

• Meticulous oral hygiene is the single most important preventive measure
• Twice-daily brushing with soft-bristled toothbrush
• Daily flossing essential
• Dental cleanings every 3-4 months (more frequent than standard 6-monthly) while on phenytoin
• Antibacterial mouthwash (chlorhexidine or similar) may help in some patients
• Powered toothbrush often more effective than manual for consistent technique
• Water flosser useful when standard flossing is difficult due to gingival overgrowth
• Regular gum health assessment by dental hygienist

🦷 Treatment of established gingival hyperplasia

• Intensified oral hygiene often reduces hyperplasia over months
• Professional dental scaling and root planing
• Surgical gingivectomy for severe cases — but recurrence rate high if hygiene inadequate
• Laser gingivectomy less traumatic than conventional surgery
• Consider switching AED to a non-hydantoin alternative if hyperplasia severe and unresponsive
• Discontinuation of phenytoin leads to slow resolution over months to years in many patients

🧪 Other AEDs and gingival hyperplasia

Gingival hyperplasia is unique to phenytoin among AEDs. Carbamazepine, valproate, lamotrigine, and levetiracetam do not cause this. This is one specific reason to consider AED alternatives in patients with severe or cosmetically distressing gingival hyperplasia. Other drugs that cause gingival hyperplasia (through different mechanisms): calcium channel blockers (nifedipine, amlodipine), cyclosporine, tacrolimus. Combination of phenytoin plus one of these drugs multiplies the risk.

🔴 SJS and TEN characteristics

Onset

Usually 1 to 8 weeks after starting phenytoin. Median approximately 3 weeks.

Prodrome

Fever, malaise, sore throat, cough for 1-3 days before rash. Often mistaken for viral illness.

Rash characteristics

Painful erythematous macules that coalesce; target lesions; skin peeling. Progresses rapidly. Mucosal involvement (mouth, eyes, genitals) always present in SJS/TEN.

SJS versus TEN definition

SJS: less than 10 percent body surface area skin detachment. SJS/TEN overlap: 10-30 percent. TEN: over 30 percent.

Mortality

SJS: approximately 5-10 percent. TEN: 25-30 percent or higher. Highest in elderly, extensive involvement, delayed care.

Long-term sequelae

Corneal scarring, dry eye syndrome, blindness; oesophageal strictures; nail changes; permanent pigmentation.

🧪 HLA-B*1502 pharmacogenomic association

Chung WH et al (Nature 2004) discovered near-100 percent association between HLA-B*1502 and carbamazepine-induced SJS/TEN in Han Chinese population. Subsequent studies confirmed similar strong association for phenytoin. Allele frequency: Han Chinese 5-15 percent, Thai 10-15 percent, Malaysian 8 percent, Vietnamese 4 percent, Indian ~2 percent, Japanese less than 1 percent, White European 0-0.1 percent, African 0-0.1 percent. FDA recommends genetic testing before phenytoin (or carbamazepine) initiation in patients of Asian ancestry.

⚠️ If HLA-B*1502 positive

• Do NOT start phenytoin or carbamazepine
• Other hydantoins (fosphenytoin) share risk
• Consider alternative AED: levetiracetam, lamotrigine (with slow titration for lamotrigine)
• Document the genetic status permanently in medical record
• Inform relatives of possible shared risk (Mendelian inheritance)
• HLA-B*1502 does NOT confer risk to other AEDs like valproate, ethosuximide, benzodiazepines

✅ If SJS/TEN suspected during therapy

• Stop phenytoin immediately
• Emergency care in burn centre or ICU
• Fluid resuscitation, wound care, nutritional support
• Ophthalmology consultation for eye care (prevent scarring)
• Dermatology consultation
• IV IgG or cyclosporine in some protocols
• Document lifetime avoidance of hydantoins, carbamazepine, aromatic anticonvulsants
• Never rechallenge; family members should be aware

🫀 DRESS syndrome characteristics

Onset

Delayed: typically 2 to 8 weeks after starting phenytoin. Late onset makes recognition challenging.

Classic features (RegiSCAR criteria)

Fever, widespread rash (often morbilliform, later exfoliative), lymphadenopathy, eosinophilia (over 1500), atypical lymphocytes on blood film, organ involvement.

Organ involvement (any of):

Hepatitis (most common; can be fulminant); myocarditis; interstitial nephritis; pneumonitis; encephalitis; pancreatitis; hypothyroidism.

Facial oedema

Characteristic feature; can be striking; often precedes full syndrome.

Course

Can persist for weeks despite drug discontinuation. Relapses can occur. Autoimmune sequelae (thyroiditis, type 1 diabetes) may develop months later.

Mortality

Approximately 10 percent, mostly from hepatic failure.

🫀 Phenytoin hepatotoxicity spectrum

• Asymptomatic LFT elevation: uncommon; usually resolves without intervention
• Isolated hepatitis: rare; part of DRESS in most cases
• DRESS-associated hepatitis: most severe presentation; can be fulminant
• Hepatic granulomas: rare
• Fulminant hepatic failure: rare but life-threatening; requires urgent transplant evaluation

🔴 Diagnostic red flags during first 8 weeks

• New fever with rash (particularly widespread morbilliform)
• Facial oedema
• Palpable lymph nodes
• Rising ALT/AST or bilirubin
• Eosinophilia (over 1500 absolute count)
• Atypical lymphocytes on blood film
• Renal function decline
• Any combination of these should trigger DRESS suspicion and immediate phenytoin discontinuation

✅ Management

• Immediate phenytoin discontinuation
• Hospital admission for monitoring
• Systemic corticosteroids (prednisolone 0.5-1 mg/kg/day, taper over months)
• Supportive care for organ dysfunction
• Never rechallenge with phenytoin or related aromatic anticonvulsants (carbamazepine, phenobarbital, lamotrigine, oxcarbazepine)
• Document syndrome in medical record and inform family members (some risk of shared HLA susceptibility)
• Follow up for autoimmune sequelae months to years later

🧪 Cross-reactivity considerations

Patients who develop DRESS from phenytoin often cross-react with related aromatic anticonvulsants: carbamazepine, phenobarbital, primidone, lamotrigine, oxcarbazepine. Alternative AED options that do not cross-react: valproate, levetiracetam, gabapentin, pregabalin, topiramate. This significantly narrows future AED options for patients with confirmed phenytoin DRESS.

💜 Purple glove syndrome characteristics

Cause

IV phenytoin has very high pH (approximately 12) and contains propylene glycol vehicle. Extravasation into subcutaneous tissue — or even proper IV administration through peripheral small veins — causes severe chemical damage.

Clinical presentation

Progressive purple discolouration of the hand or limb starting at IV site. Pain, oedema, cold or cyanotic extremity, delayed capillary refill. Progression to necrosis over 24-72 hours if untreated.

Risk factors

Peripheral IV administration (particularly small veins in hand); rapid infusion rate; existing vascular disease; elderly patients with fragile veins; long duration IV therapy.

Onset timing

Discolouration typically noted within hours of IV administration. Full syndrome develops over 24-72 hours.

Severity spectrum

From mild transient discolouration to severe necrosis requiring fasciotomy, skin grafting, or amputation.

🔴 Prevention strategies

• Use fosphenytoin instead of IV phenytoin whenever possible — substantially lower risk
• Use central venous access when IV phenytoin is chosen and available
• Large-bore peripheral IV in antecubital fossa if central not available; avoid hand/wrist veins
• Do not exceed 50 mg/min infusion rate (adults; lower in children and elderly)
• Dilute in normal saline, never in dextrose (precipitates)
• Direct visualisation of IV site during infusion — monitor for pain, discolouration, extravasation
• Follow immediately with saline flush
• Do not use existing IV site for other medications immediately before or after

⚠️ If extravasation or purple glove syndrome develops

• Stop infusion immediately
• Do NOT remove the IV catheter initially — use it to aspirate any residual drug from the tissue
• Elevate the limb
• Warm compresses (some centres) or cold (others) — local protocols vary
• Vascular surgery consultation urgently if progressive discolouration or oedema
• Consider hyaluronidase injection at extravasation site (may help disperse drug)
• Serial neurovascular checks every hour for 24 hours
• Compartment pressure measurement if concerns about compartment syndrome
• Prepare for possible fasciotomy in severe cases

🧪 Fosphenytoin as the answer

Fosphenytoin (Cerebyx) was developed specifically to address this problem. Its water-soluble form allows administration through peripheral IV without the caustic effects. In well-resourced hospitals, fosphenytoin has replaced IV phenytoin as standard of care for parenteral hydantoin therapy. In cost-limited settings where IV phenytoin remains in use, strict adherence to prevention protocols is essential to avoid this dreaded complication.

🦴 Phenytoin bone effects mechanism

CYP450 induction

Phenytoin induces hepatic vitamin D metabolism, accelerating conversion of 25-hydroxyvitamin D to inactive metabolites. Result: reduced active vitamin D levels.

Reduced calcium absorption

Low vitamin D leads to reduced intestinal calcium absorption. Additional direct effects on gut calcium transport also documented.

Secondary hyperparathyroidism

Low calcium triggers parathyroid hormone rise, mobilising calcium from bone. Chronic PTH elevation drives bone loss.

Direct osteoblast effects

Phenytoin also has direct effects on osteoblast function contributing to reduced bone formation.

Cumulative effect

Effects develop over years of chronic use. Substantial bone density loss can occur before symptoms develop.

🔴 Clinical consequences

• Increased fracture risk (particularly hip, vertebral, wrist)
• Osteoporotic fractures with minimal trauma
• Vertebral compression fractures causing height loss and back pain
• Osteomalacic bone pain
• Muscle weakness (proximal muscle weakness from hypocalcaemia)
• Impaired healing of fractures
• Rare rickets in children on chronic phenytoin

🔬 Class effect among enzyme-inducing AEDs

Bone effects are shared by other enzyme-inducing AEDs: phenobarbital, carbamazepine, primidone. Non-inducing AEDs (levetiracetam, lamotrigine, gabapentin, pregabalin, valproate) do not appear to cause the same bone density effects. This is one of the increasingly cited reasons to prefer newer non-inducing AEDs for long-term epilepsy management, particularly in patients at risk of osteoporosis (postmenopausal women, elderly, those with additional risk factors).

✅ Practical approach for chronic users

For patients starting phenytoin for long-term therapy: (1) baseline vitamin D level with supplementation to normalise; (2) routine vitamin D 1000-2000 IU daily plus calcium 1000-1200 mg/day; (3) baseline DEXA after 3-5 years; (4) treat osteoporosis with bisphosphonate if identified. This proactive approach substantially reduces the fracture risk over decades of therapy. In practice, many patients on chronic phenytoin are still not adequately monitored for bone effects — this is an area of quality improvement in epilepsy care.

🧠 Acute cerebellar toxicity

Horizontal nystagmus

Earliest sign of phenytoin toxicity. Typically appears at levels above 20 mcg/mL. Elicited on lateral gaze. Should prompt dose reassessment.

Ataxia and incoordination

Appears at levels 30 mcg/mL or above. Wide-based gait, dysmetria on finger-to-nose testing, difficulty with tandem walking. Reduced dose reverses this.

Slurred speech

Dysarthria at levels above 30 mcg/mL. Combined with ataxia may resemble acute intoxication.

Sedation and encephalopathy

At levels above 40 mcg/mL. Lethargy, confusion, and eventually coma. Reversible with dose reduction if recognised.

Paradoxical seizure worsening

At very high levels (over 40 mcg/mL) phenytoin can paradoxically increase seizures — a challenging clinical scenario resembling AED failure but requiring dose reduction, not increase.

🔴 Chronic cerebellar atrophy

Radiographic finding

MRI of brain shows cerebellar atrophy (typically vermian) in a subset of patients on long-term phenytoin. May occur even at therapeutic levels over years.

Clinical presentation

Slowly progressive ataxia, gait instability, coordination difficulties. Can persist or worsen even after phenytoin discontinuation.

Risk factors

Long duration therapy (years to decades); repeated episodes of toxic levels; older age; concomitant seizure disorder itself may contribute.

Reversibility

Partially reversible in some patients after phenytoin discontinuation; other patients have permanent atrophy and residual ataxia.

Mechanism

Cerebellar Purkinje cell loss from sustained phenytoin exposure. Related to sodium channel effects in cerebellum.

🔬 Practical implications

The chronic cerebellar atrophy concern is one reason modern epilepsy practice increasingly favours newer non-inducing AEDs over phenytoin for lifetime maintenance therapy. In patients on chronic phenytoin, meticulous level monitoring to avoid toxic levels, and periodic assessment of gait and coordination, help detect early cerebellar changes. If new ataxia or gait changes develop in a chronic user, MRI brain to assess for cerebellar atrophy and consideration of AED switch may be appropriate.

✅ Monitoring approach

For patients on chronic phenytoin: (1) periodic gait and coordination assessment during routine visits; (2) prompt dose adjustment if nystagmus develops; (3) MRI brain if new persistent ataxia develops; (4) documented history of prolonged toxic levels as risk factor to consider; (5) discussion of AED switch if cerebellar concerns arise. Prevention is achievable through disciplined level monitoring and dose control over years of therapy.

📈 Cosmetic effects of chronic phenytoin

Hirsutism

Excessive hair growth on face (particularly upper lip, chin, sideburns), arms, back, and legs. Coarser darker hair. Affects both sexes but more distressing in women. Develops over months of therapy.

Coarsening of facial features

Broadening of nose, thickened lips, enlarged brows, prominent forehead, wider jaw. Develops slowly over years. Sometimes described as "phenytoin facies." May not be fully reversible after discontinuation.

Acne

Can develop or worsen with phenytoin therapy. Particularly troublesome in adolescents.

Skin changes

Thickened, sometimes greasy skin. Increased sweating in some patients.

Reversibility

Hirsutism partially reverses over months to years after discontinuation. Coarsening of features may be permanent or only partially reversible.

📈 Impact considerations

• Adolescents: cosmetic effects during body-image development can be particularly distressing
• Young women: hirsutism and coarsening affect femininity concerns
• Chronic users: cumulative effect over decades
• Combined with gingival hyperplasia: multiple visible effects together
• Contribution to noncompliance: patients may reduce or stop phenytoin due to cosmetic concerns
• Consideration for AED switch: important discussion for long-term maintenance

✅ Management approach

• Cosmetic hair removal: waxing, threading, laser hair removal, electrolysis
• Facial hair depilation: eflornithine cream may slow facial hair growth
• Skin care: address any secondary acne with standard dermatology
• Openly discuss cosmetic effects with patients before starting long-term therapy
• Consider alternative AED for young women, adolescents, or cosmetically-concerned patients
• Newer AEDs (levetiracetam, lamotrigine, oxcarbazepine) do NOT cause hirsutism or coarsening
• Psychosocial support if cosmetic effects significantly impact quality of life

🧪 Unique to hydantoins

Hirsutism and coarsening of features are relatively unique to phenytoin and other hydantoins among AEDs. Carbamazepine, valproate, lamotrigine, levetiracetam, and other newer agents do not cause these effects. This distinction is one of the strongest arguments for choosing a non-hydantoin AED when cosmetic concerns are relevant, particularly for young women and adolescents facing decades of potential AED therapy.

⚠️ Preconception counselling

For a young woman being considered for lifetime AED therapy, discuss cosmetic effects openly before starting phenytoin. Many patients would prefer a different AED once they understand the potential for gingival hyperplasia, hirsutism, coarsening of features, and osteomalacia. Newer AEDs offer these advantages plus better teratogenicity profiles for potential future pregnancies. Making these decisions before starting phenytoin is easier than switching after adverse effects develop.

🔴 The suspension shaking imperative

Phenytoin oral suspension separates on standing, with concentrated drug settling to the bottom. If not shaken vigorously before each dose, early doses from a bottle can be sub-therapeutic and later doses (from the concentrated bottom) can cause toxicity. This has been documented as a real source of variable levels, breakthrough seizures, and toxicity in paediatric patients. Shake for a full minute vigorously before each dose.

📦 Practical storage rules

• Original blister packaging or bottle for extended storage of capsules and tablets
• Cool, dry location (not bathroom cabinet)
• Keep out of reach of children
• Do not use tablets with damaged coating or altered appearance
• Discard past printed expiration date
• Travel-friendly at typical ambient temperatures
• Oral suspension: keep upright; do not freeze; shake before each dose
• IV vials: do not refrigerate (precipitates); dilute in saline immediately before use; use within 1 hour

🧪 Generic vs brand formulation consistency

Different manufacturers' extended-release phenytoin capsules may have slightly different bioavailability profiles. Because phenytoin has non-linear kinetics and narrow therapeutic index, even small bioavailability differences can cause meaningful level changes. Best practice: use the same manufacturer's formulation consistently for chronic maintenance. If switching between brand and generic (or between generics), check level 2-4 weeks after switch and adjust dose if needed. This is one AED where brand consistency matters more than for most drugs.

✅ Practical patient counselling

Emphasise to patients and families: (1) shake suspension vigorously for a full minute before every dose; (2) use the same brand/formulation consistently; (3) do not stop phenytoin abruptly (rebound seizures); (4) do not double dose after missed dose (see missed dose section); (5) store away from moisture and heat; (6) inform pharmacist about any change in appearance of tablets/capsules; (7) never share medication with others.

⏰ Missed dose rules

Once daily regimen

If less than 12 hours late: take as soon as remembered. If more than 12 hours late: skip and take next dose at usual time. Do not double up.

Twice daily regimen (BID)

If less than 6 hours late: take as soon as remembered. If more than 6 hours late: skip and take next dose at usual time. Do not double up.

Three times daily regimen (TID)

If less than 3 hours late: take as soon as remembered. If more than 3 hours late: skip and take next dose at usual time. Do not double up.

Multiple doses missed

If missed doses have caused breakthrough seizures, urgent consultation with prescriber. If asymptomatic, resume regular schedule; check level in 1-2 weeks. Do not attempt to make up missed doses.

Vomiting after dose

If within 30 minutes of dose: probably re-dose (call prescriber for guidance). If longer than 1 hour: consider dose absorbed; do not re-dose.

🔴 NEVER double dose

Due to phenytoin's non-linear kinetics, doubling a dose to compensate for a missed one can cause dangerous toxicity. The metabolic enzymes are already saturated at therapeutic levels; adding an extra dose can drive levels far above therapeutic range. Never double up.

🔴 Never stop phenytoin abruptly

Abrupt discontinuation of phenytoin in patients with epilepsy can trigger rebound seizures or status epilepticus. Even if switching to a new AED, phenytoin should be tapered gradually while the new drug is being established. Only in cases of severe adverse reactions (SJS, DRESS, severe hepatotoxicity) is immediate discontinuation required — in which case another AED should be started urgently.

💡 Adherence tips

• Anchor doses to routine activities (breakfast, dinner)
• Set phone alarms for each dose time
• Use pill organiser (weekly) for tablet forms
• Keep spare doses at work, in bag, at home
• For suspension: shake for full minute before each dose
• Take with meals to reduce GI upset
• Discuss with prescriber if adherence is problematic — may need dose adjustment or extended-release formulation
• Never skip doses due to feeling well — seizure control depends on consistent levels
• Regular therapeutic drug monitoring — abnormal levels may indicate adherence issues

🧪 Consequence of missed doses

Because phenytoin has a relatively long half-life at therapeutic levels (up to 60+ hours), missing one dose does not immediately drop levels below therapeutic threshold. However, repeated missed doses over days can lead to breakthrough seizures. Missing doses is a common cause of unexpected seizures in previously well-controlled patients. Any patient with breakthrough seizures should be asked carefully about adherence before assuming AED failure.

🔴 Key concerns in older adults

• Reduced albumin: raises free phenytoin; total level underestimates active drug
• Reduced hepatic metabolism: prolonged half-life; slower steady state after dose changes
• Polypharmacy interactions: many drugs raise or lower phenytoin levels
• Cognitive vulnerability: cognitive slowing more prominent
• Fall risk: cerebellar effects add to existing fall risk from other causes
• Osteoporosis: pre-existing bone loss worsened by chronic phenytoin
• Cardiovascular disease: IV phenytoin cardiovascular effects more dangerous
• Reduced ability to monitor: may not report early toxicity signs

👴 Geriatric prescribing framework

• For newly diagnosed epilepsy in elderly: prefer levetiracetam or lamotrigine over phenytoin
• For status epilepticus in elderly: fosphenytoin preferred over IV phenytoin for cardiovascular safety
• For elderly stable on chronic phenytoin: continue if tolerating; do not switch without reason
• Free phenytoin level monitoring more reliable than total in elderly with low albumin
• Lower starting doses: 3-4 mg/kg/day (vs 4-6 mg/kg/day in adults)
• Slower dose titration: 2-4 weeks between adjustments
• Falls assessment: baseline gait, balance, home safety
• Bone density monitoring: DEXA scan for chronic users

✅ Bottom line for older adults

In modern practice, phenytoin is often NOT the first choice for newly diagnosed epilepsy in older adults. Levetiracetam is generally preferred due to fewer interactions, linear kinetics simplifying dosing, no protein binding complications, and no cognitive concerns at typical doses. Lamotrigine is another good option for elderly. For elderly patients already stable on chronic phenytoin, careful continuation with monitoring is reasonable. For emergency parenteral use, fosphenytoin is preferred over IV phenytoin given cardiovascular safety.

👶 Paediatric special populations

Neonates

Neonatal seizures: phenytoin or phenobarbital second-line after benzodiazepines. Metabolism is variable and often prolonged. IV/oral loading 15-20 mg/kg followed by maintenance 5-8 mg/kg/day divided BID. Level monitoring essential.

Infants and toddlers

More rapid metabolism than adults on mg/kg basis. Requires higher weight-based doses. Suspension form typically used — strict shaking protocol required.

School-age children

Cosmetic effects (gingival hyperplasia, hirsutism) particularly relevant. Discuss with parents. Newer AEDs often preferred for chronic maintenance.

Adolescents

Cosmetic concerns paramount; adherence issues with visible side effects. Oral contraceptive interaction important in females. Newer AEDs strongly preferred for chronic use.

Adolescent females of childbearing age

Teratogenicity + contraceptive failure + cosmetic effects — multiple reasons to avoid phenytoin. Lamotrigine or levetiracetam preferred.

Children with cognitive delays

Phenytoin cognitive effects may worsen existing delays. Newer AEDs with less cognitive impact preferred.

Asian ancestry paediatric patients

HLA-B*1502 screening before starting; alternative if positive.

Post-traumatic seizure prophylaxis paediatric

7-day phenytoin protocol acceptable; levetiracetam increasingly preferred alternative.

🔴 Paediatric-specific concerns

• Cosmetic effects (gingival, hirsutism, coarsening) very distressing in adolescents
• Suspension dosing errors (settling) commonly seen
• Growth-related dose changes needed regularly
• Contraceptive failure risk in female adolescents
• Cognitive slowing may affect school performance
• Bone development effects with prolonged use
• Behavioural effects less than with levetiracetam (advantage)

✅ Paediatric counselling essentials

• Explain the specific indication and expected duration
• Give suspension only after vigorous shaking (full minute)
• Use provided dosing device (syringe or cup)
• Emphasise consistent formulation and manufacturer
• Meticulous dental hygiene from start
• Regular dental cleanings every 3-4 months
• Report new rash promptly (SJS/TEN)
• Report unusual features (facial swelling, fever, lymphadenopathy) — DRESS
• Regular level monitoring during growth phases
• Discuss cosmetic effects openly — may motivate switch to newer AED
• Contraceptive counselling for adolescent females

⛔ Do not use phenytoin

• Prior SJS, TEN, or DRESS from phenytoin or related aromatic AEDs
• Prior anaphylaxis or hypersensitivity to phenytoin
• Prior phenytoin-induced hepatotoxicity
• HLA-B*1502 positive (Asian populations)
• Absence seizures
• Myoclonic seizures
• Juvenile myoclonic epilepsy first-line
• Sinus bradycardia or second/third degree heart block (IV administration)
• Prior purple glove syndrome
• Severe hepatic failure

🟡 Consider alternative

• Newly diagnosed epilepsy in adult with modern AED options (prefer levetiracetam or lamotrigine)
• Women of childbearing age (prefer lamotrigine or levetiracetam)
• Adolescents and children (cosmetic effects; prefer newer AEDs)
• Elderly with polypharmacy (prefer levetiracetam with fewer interactions)
• Patients with existing osteoporosis (avoid enzyme-inducing AEDs)
• Patients with cognitive concerns (prefer AEDs with better cognitive profile)
• Patients needing to remain on hormonal contraception
• Cost-sensitive settings where levetiracetam generics are affordable
• Emergency IV situations where fosphenytoin is available (safer parenteral option)

✅ Where phenytoin genuinely retains a role

Status epilepticus emergency treatment as second-line after benzodiazepines (or fosphenytoin preferred); post-traumatic seizure prophylaxis 7-day protocol; perioperative seizure prevention after supratentorial neurosurgery; chronic epilepsy in patients stable on phenytoin for years and tolerating well; cost-limited settings where phenytoin generics are the only affordable AED; patients who cannot tolerate levetiracetam behavioural effects.

🔄 Common alternatives

For newly diagnosed focal epilepsy: levetiracetam or lamotrigine first-line. For primary generalized epilepsy: valproate (men), lamotrigine, or levetiracetam (women). For juvenile myoclonic epilepsy: valproate (men), lamotrigine or levetiracetam (women); NEVER phenytoin. For absence: ethosuximide or valproate. For status epilepticus: fosphenytoin, valproate, or levetiracetam (per ESETT). For post-traumatic prophylaxis: phenytoin or levetiracetam both acceptable. For trigeminal neuralgia: carbamazepine or oxcarbazepine first-line.

🔭 Modern role in perspective

Ongoing niche in acute settings

Status epilepticus and post-traumatic seizure prophylaxis remain areas where phenytoin (or fosphenytoin) has established protocols and continues to be widely used.

Displaced by newer AEDs for chronic maintenance

Levetiracetam and lamotrigine have become first-line for newly diagnosed epilepsy in developed markets. Phenytoin remains an alternative but is prescribed less frequently for new-onset patients.

Continued importance in resource-limited settings

In many low- and middle-income countries, phenytoin remains a mainstay of epilepsy treatment due to extremely low cost and WHO Essential Medicine status. Global epilepsy burden is greatest in these settings.

Long-term stable users

Many patients on chronic phenytoin from before newer AEDs became available continue on it. Do not switch working therapy without reason.

Continued research and monitoring

Understanding of long-term effects (bone density, cerebellar, cognitive) continues to evolve. Optimising phenytoin use in patients who remain on it is an ongoing quality improvement area.

✅ Overall value

Phenytoin (Dilantin) represents one of the most historically important antiepileptic drugs in medical history. Its 1938 discovery transformed epilepsy treatment from an era of sedating bromides and barbiturates to modern non-sedating seizure control. For nearly nine decades it has enabled millions of people with epilepsy to lead functional lives. In the era of newer AEDs with better safety profiles, phenytoin's role has narrowed but not disappeared. It remains critically important for status epilepticus emergency management, post-traumatic seizure prophylaxis, cost-sensitive chronic epilepsy management globally, and patients stable on established phenytoin therapy. Modern practice balances its established efficacy against its substantial adverse effect burden, individualising treatment through careful monitoring, therapeutic drug levels, and patient-specific decision-making. Its WHO Essential Medicine status ensures continued global availability for the acute and chronic seizure indications where it remains valuable. For appropriate patients matched to appropriate indications with proper monitoring, phenytoin continues to deliver reliable, cost-effective anticonvulsant therapy that decades of clinical experience have refined.

⛔ Absolute contraindications

Prior SJS, TEN, or DRESS from phenytoin or related AEDs

Lifetime avoidance of hydantoins and aromatic anticonvulsants.

Prior anaphylaxis to phenytoin

Lifetime avoidance.

Prior severe hepatitis from phenytoin

Do not rechallenge.

Prior purple glove syndrome

Use fosphenytoin only; central line preferred.

Sinus bradycardia, second or third degree AV block (for IV)

Do not use IV; oral acceptable if oral tolerated.

Absence seizures

Can worsen; use ethosuximide or valproate.

Myoclonic seizures / juvenile myoclonic epilepsy

Can worsen; use valproate, levetiracetam, or lamotrigine.

HLA-B*1502 positive (Asian populations)

100-fold SJS/TEN risk; use alternative AED.

🟡 Relative contraindications and cautions

Pregnancy

Category D; fetal hydantoin syndrome; use alternative if possible; if continued, folate supplementation.

Women of childbearing age

Contraceptive failure risk; teratogenicity; use alternative AED if possible.

Adolescents

Cosmetic effects; prefer newer AEDs.

Severe hepatic impairment

Complex pharmacokinetics; consider alternative AED.

Renal impairment / hypoalbuminaemia

Monitor free levels; use Sheiner-Tozer correction if only total available.

Concurrent CYP inhibitor drugs

Raise phenytoin levels; monitor carefully; consider dose reduction.

Concurrent valproate

Protein displacement; check free level.

Enteral tube feeding

Reduced absorption; hold feeds 1-2 hours around doses.

Elderly with polypharmacy

Interaction risk; falls; consider alternative AED.

Cardiovascular disease

IV administration risks; use fosphenytoin over IV phenytoin.

Chronic use in general

Long-term cosmetic, cognitive, bone, cerebellar effects; consider alternatives.

📋 Populations requiring extra care

• Asian ancestry (HLA-B*1502 screening)
• Women of childbearing age
• Pregnant women (Category D)
• Adolescents (cosmetic effects)
• Elderly with polypharmacy
• Patients with hepatic or renal impairment
• Patients on multiple interacting medications
• Patients with pre-existing osteoporosis
• Chronic long-term users (cumulative effects)
• Patients receiving IV in peripheral vein (purple glove risk)
• Patients with juvenile myoclonic epilepsy or absence seizures (contraindicated)